ClinicalTrials.gg
Sign In
RecruitingNCT07759895IronManUpdated Sep 29, 2026

Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia

A Phase 2 interventional study of Deferiprone (DFP) and N-Acetyl Cysteine (NAC) in Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder and Schizophrenia and Predominant Negative Symptoms, sponsored by Amit Lotan. Recruiting at 2 sites in Israel. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Amit Lotan · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator DFP plus NAC or a matching placebo plus NAC combination, as add-on to their maintenance antipsychotic drug (APD) treatment, for a duration of 36 weeks. Prior to initiation of treatment, all participants will undergo baseline MRI scan. A follow-up MRI will be conducted at the end of the 36-week study period, or upon early withdrawal if applicable, to evaluate the effect of the add-on treatment on iron dyshomeostasis and morphology.

Read the detailed description

The present study is designed as an interventional trial over a 36-week period per patient. The target populThe present study is designed as an interventional trial over a 36-week period per patient. The target population consists of patients with schizophrenia (age 18-40 years), up to ten years since onset of positive symptoms. The overall objective of the study is to assess the safety and efficacy of DFP-NAC combination add-on in patients with schizophrenia, compared to NAC-only add-on (control group). This study is designed to test the hypothesis that, in patients with prominent negative symptoms, adjunctive treatment with DFP-NAC combination will demonstrate a favorable safety profile and produce clinical improvements in negative and cognitive domains of schizophrenia beyond those offered by addition of NAC alone.ation consists of patients with schizophrenia (age 18-40 years), up to ten years since onset of positive symptoms. The overall objective of the study is to assess the safety and efficacy of DFP-NAC combination add-on in patients with schizophrenia, compared to NAC-only add-on (control group). This study is designed to test the hypothesis that, in patients with prominent negative symptoms, adjunctive treatment with DFP-NAC combination will demonstrate a favorable safety profile and produce clinical improvements in negative and cognitive domains of schizophrenia beyond those offered by addition of NAC alone.

02

Conditions studied

  • Schizoaffecitve Disorder
  • Schizophrenia and Schizoaffective Disorder
  • Schizophrenia and Predominant Negative Symptoms

Keywords

  • Deferiprone
  • N-acetylcysteine
  • Schizophrenia
  • Clinical Trial
  • negative symptoms
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 80 is above the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

This is the only study on the registry with Amit Lotan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-55 years.
  2. Diagnosis of schizophrenia/schizoaffective disorder according to the - Fifth Edition (DSM-5) criteria. The diagnostic assessment will be conducted using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT).
  3. Adequate antipsychotic treatment for ≥ 4 months prior to screening (excluding clozapine use).
  4. Stable dose of antipsychotic medication for ≥ 8 weeks prior to screening (excluding clozapine use).
  5. When relevant, stable dose of antidepressants, mood stabilizers and benzodiazepines/Z-drugs for ≥ 8 weeks prior to screening.
  6. Screening and baseline PANSS total score ranging from 60 to 120.
  7. Sum ≥ 20 for the 7 items in the Negative Symptoms subscale of the PANSS.
  8. At least two items in the PANSS Negative Symptoms subscale scored ≥ 4.
  9. Sum \< 20 for the 7 items in the Positive Symptoms subscale of the PANSS.
  10. Score ≤ 5 for each item in the Positive Symptoms subscale of the PANSS.
  11. Calgary Depression Schizophrenia Scale (CDSS) score of ≤ 6.
  12. Persistent and predominant negative symptoms for ≥ 6 months, in the opinion of the investigator
  13. The subject exhibits clinical stability in both positive and negative symptoms of schizophrenia over the past 6 months, as assessed by the treating psychiatrist and supported by documentation in the medical record.
  14. No incarceration in prison or acute crisis intervention due to symptom exacerbation within 6 months of screening. The subject must be considered psychiatrically stable in the opinion of the investigator.

  15. For males or women, either of the following:

    1. Serum ferritin ≥30 ng/mL at screening. OR
    2. Serum ferritin 15-29 ng/mL at screening, provided that:

    i. An evaluation of potential underlying causes as well as potentially comorbid deficiencies has been completed, including assessment of folate, vitamin B12, celiac antibodies and H. pylori infection, and, in patients over 40 years old or with positive family history of colorectal cancer, also an appropriate colorectal screening test, alongside other tests deemed as relevant by the investigator; ii. Identified causes have been appropriately managed; iii. Repeated ferritin assessment prior to randomization remains within the range of 15-29 ng/mL; and iv. Oral iron supplementation is initiated according to the study protocol.

  16. For premenopausal women: Serum ferritin ≥15 ng/mL at screening.
  17. Screening serum ≥ 13g/dL for males, ≥ 12g/dL for females
  18. Use of in women of childbearing age.
  19. Ability to provide , confirmed by a non-study psychiatrist. When a subject is under guardianship, both patient assent and guardian consent are required. Obtaining written informed consent, dated and signed, is mandatory prior to the initiation of any procedures related to the clinical trial.
  20. Ability to safely undergo MRI scanning, assessed by a non-study psychiatrist.
  21. In the Investigator's opinion, the subject can understand the nature of the trial, comply with study drug administration and protocol procedures or has a guardian able to assist.
  22. Availability of a reliable caregiver or other responsible person (e.g., family member, social worker, nurse) to support treatment adherence and provide collateral information for rating scales.

Exclusion criteria

Exclusion criteria:

  1. Primary diagnosis other than schizophrenia or schizoaffective disorder in the 12 months prior to screening, according to SCID-5-CT.
  2. Subjects diagnosed with Autistic Spectrum Disorder (ASD).
  3. Subjects diagnosed with Intellectual Developmental Disorder.
  4. Patients who received clozapine within the 6 months preceding the screening.
  5. Patients with a history of relapsing neutropenia (Absolute Neutrophile Count (ANC) \< 1,500 cells/µL)
  6. Screening ANC ≤ 2,000 cells/µL.
  7. Non-compliance during run-in period (percent adherence ≤ 80%, as examined by pill count).
  8. Improvement > 20% in PANSS total score or PANSS negative subscale during the run-in period.
  9. Suicide attempt or serious suicidal behavior within the past 12 months.
  10. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  11. The subject has a history of substance use disorder or any illicit drug use (other than nicotine) within the past 3 years.
  12. Positive urine drug screen for drugs of abuse (cocaine, methadone, amphetamines, cannabinoids, opiates, and barbiturates).
  13. Risk of violent behavior in the opinion of the Investigator.
  14. Known to deferiprone or N-Acetylcysteine.
  15. Pregnancy or intention to become pregnant during the study duration.
  16. Female patients who are lactating.
  17. ECT treatment within 18 weeks prior to screening and study entry.
  18. Patient with substantially confounding extrapyramidal symptoms (according to screening SAS, BARS, AIMS score).
  19. Conditions that are not suitable for partaking in an MRI scan, including metal implants and incompatible devices.
  20. Subjects with ≤ 18 or ≥ 40.
  21. Participation in another clinical trial involving drugs within 3 months prior to screening.
  22. general medical conditions (neurological, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, oncologic) that could interfere with participation.
  23. Major active contagious disease.
  24. Patients with clinically significant abnormalities in hematology, blood chemistry, or physical examination, not resolved by the Baseline visit, that can interfere with study participation.
  25. Any condition that, in the investigator's judgment, may compromise subject safety or interfere with study assessments.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo + N-Acetylcysteine

    Drug: N-Acetyl Cysteine (NAC)

  • Active comparator
    Deferiprone + N-Acetylcysteine

    Drug: Deferiprone (DFP) · Drug: N-Acetyl Cysteine (NAC)

Interventions

  • DrugDeferiprone (DFP)

    This intervention has not been used before on Schizophrenia or Schizoaffective patients with predominant negative symptoms.

  • DrugN-Acetyl Cysteine (NAC)

    This drug is given to both groups.

06

What researchers measure

Primary outcomes

  1. Change in Total PANSS Score

    Change from Baseline to Week 36 in the PANSS (Positive and Negative Syndrome Scale) total score. PANSS total score range: 30 to 210 (30 items, each rated 1-7, so minimum 30 and maximum 210). Higher scores indicate more severe symptoms.

    Time frame: 36 Weeks (LOCF)

Secondary outcomes

  1. PANSS Marder Negative Symptom Factor Score

    Change from Baseline in the PANSS Marder Negative Symptom Factor Score (NSF)

    Time frame: 12, 24 and 36 weeks

  2. PANSS Positive Subscale Score

    Change from Baseline in the PANSS Positive sub-scale score

    Time frame: 12, 24 and 36 weeks

  3. PANSS Negative Subscale Score

    Change from Baseline in the PANSS Negative sub-scale score

    Time frame: 12, 24 and 36 weeks

  4. PANSS General Psychopathological Subscale Score

    Change from Baseline in the PANSS General Psychopathological sub-scale score

    Time frame: 12, 24 and 36 weeks

  5. BNSS (Brief Negative Symptom Scale) Score

    Change from Baseline in the BNSS (Brief Negative Symptom Scale) score

    Time frame: 12, 24 and 36 weeks

  6. BACS (Brief Cognitive Assessment in Schizophrenia) Score

    Change from Baseline in the BACS (Brief Cognitive Assessment in Schizophrenia) score

    Time frame: 12, 24 and 36 weeks

  7. Reported adverse events (descriptive)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  8. Weight (kg)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  9. Height (cm)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  10. BMI (Body Mass Index, kg/cm^2)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  11. Blood pressure (mm Hg)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  12. Heart rate (BPM)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  13. Electrocardiogram (ECG)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  14. Complete Blood Count (CBC)

    Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  15. Serum creatinine

    kidney function test, mg/dL, Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  16. Serum alanine transaminase

    ALT, liver function test, U/L, Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  17. Serum ferritin

    iron store index, ng/mL, Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  18. Simpson-Angus Extrapyramidal Rating Scale (SAS)

    10 items, each 0-4, Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  19. Barnes Akathisia Rating Scale (BARS)

    Global clinical assessment of akathisia (0-5), Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  20. Abnormal Involuntary Movement Scale (AIMS)

    Items counted: 7, Per-item range: 0-4, Total (sum) range: 0-28, Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  21. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Ideation severity: 0-5, Ideation intensity (sum): 0-25, Behavior: categorical (yes/no; counts), Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  22. Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU-SERS )

    Per item range: 0-3 (0 = none, 1 = mild, 2 = moderate, 3 = marked/severe), Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  23. Discontinuation-Emergent Signs and Symptoms (DESS)

    43-item checklist: each symptom is scored 0/1 (absent/present), total range 0-43; Safety and tolerability assessment

    Time frame: From enrollment to the end of treatment at 36 weeks

  24. Quantitative MRI - Proton Density (PD)

    PD is normalized to derive the water fraction (WF); WF yields the Macromolecular Tissue Volume (MTV). These reflect the ratio of water to non water tissue and act as biomarkers of atrophy or density

    Time frame: baseline, 36 weeks

  25. Quantitative MRI - R1 (Longitudinal Relaxation Rate)

    R1 is sensitive to myelin, iron and water content. R1 and MTV are acquired using the same variable flip angle or/and MP2RAGE sequences, which can also include MT and multi echo acquisitions for R2\* and QSM

    Time frame: Baseline, 36 weeks

  26. Quantitative MRI - Magnetization Transfer (MT)

    MT modeling estimates the macromolecular contribution to R1, yielding MTsat. Combined with R1 and MTV, this enables R1sat and MTVsat estimation, providing contrast related to saturated vs. unsaturated water pools

    Time frame: Baseline, 36 weeks

  27. Quantitative MRI - R2*

    R2\* is influenced by magnetic field inhomogeneities and is sensitive to iron deposition and other sources

    Time frame: Baseline, 36 weeks

  28. Quantitative MRI - Quantitative Susceptibility Mapping (QSM)

    QSM estimates tissue magnetic susceptibility from R2\* data and is sensitive to iron, calcium and related tissue properties

    Time frame: Baseline, 36 weeks

  29. Quantitative MRI - R2 (Transverse Relaxation Rate)

    R2 reflects tissue integrity and is influenced by myelin and iron. Multi-component fitting allows estimation of Myelin Water Fraction (MWF)

    Time frame: Baseline, 36 weeks

  30. Quantitative MRI - R1-R2 Relaxivity

    The voxel-wise slope of R1 vs. R2\* within an ROI (R1-R2\* relaxivity) can reflect specific iron forms

    Time frame: Baseline, 36 weeks

  31. Quantitative MRI - Tissue Relaxivity (MTV Dependency)

    Parameter-MTV slope (MDM: Multidimensional Dependency on MTV) reflects lipid and macromolecular composition

    Time frame: Baseline, 36 weeks

  32. Quantitative MRI - Diffusion MRI

    Mean Diffusivity (MD)

    Time frame: Baseline, 36 weeks

  33. Quantitative MRI - Diffusion MRI

    Fractional Anisotropy (FA)

    Time frame: Baseline, 36 weeks

  34. Quantitative MRI - G-Ratio Mapping

    Combines diffusion (axon density) and qMRI (myelin) data to estimate the g-ratio: the ratio of axon to fiber diameter

    Time frame: Baseline, 36 weeks

  35. Quantitative MRI - Macroscopic Morphometry

    Cortical volume

    Time frame: Baseline, 36 weeks

  36. Quantitative MRI - Neuromelanin-Sensitive MRI (NM-MRI)

    T1-weighted or MT-enhanced sequences detect neuromelanin in the substantia nigra and locus coeruleus; used to assess catecholaminergic neuron integrity

    Time frame: Baseline, 36 weeks

  37. Magnetic Resonance Spectroscopy (MRS)

    Estimates concentrations of brain metabolites

    Time frame: Baseline, 36 weeks

Other outcomes

  1. Proportion of patients showing a PANSS response of ≥30% reduction

    Proportion of patients showing a PANSS response of ≥30% reduction in corrected PANSS total score (PANSS total minus 30)

    Time frame: 12, 24 and 36 weeks

  2. CDSS (Calgary Depression Scale for Schizophrenia) Scale

    Change from Baseline in CDSS (Calgary Depression Scale for Schizophrenia) scale

    Time frame: 12, 24 and 36 weeks

  3. CGI-Schizophrenia (CGI-SCH) : Negative Symptoms Severity of Illness sub-scale

    Change from Baseline in the CGI-Schizophrenia (CGI-SCH) Scale : Negative Symptoms - Severity of Illness sub-scale; Scale: 1-7; 1 = Normal, not ill; 7 = Among the most extremely ill patients

    Time frame: 12, 24 and 36 weeks

  4. CGI-Schizophrenia (CGI-SCH) : Overall Severity of Illness sub-scale

    Change from Baseline in the CGI-Schizophrenia (CGI-SCH) Scale : Overall Severity of Illness sub-scale; Scale: 1-7; 1 = Normal, not ill; 7 = Among the most extremely ill patients

    Time frame: 12, 24 and 36 weeks

  5. CGI-Schizophrenia (CGI-SCH) : Overall Degree of Change sub-scale

    Change from Baseline in the CGI-Schizophrenia (CGI-SCH) Scale : Overall Degree of Change sub-scale; Scale: 1-7, 1 = Very much improved, 4 = No change, 7 = Very much worse

    Time frame: 12, 24 and 36 weeks

  6. Personal and Social Performance (PSP) Scale

    Change from Baseline in Personal and Social Performance (PSP) scale

    Time frame: 12, 24 and 36 weeks

  7. Self-evaluation of Negative Symptoms (SNS) Scale

    Change from Baseline in the Self-evaluation of Negative Symptoms (SNS) scale

    Time frame: 12, 24 and 36 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Beebe LH, Smith K. Informed consent to research in persons with schizophrenia spectrum disorders. Nurs Ethics. 2010 Jul;17(4):425-34. doi: 10.1177/0969733010364581. PubMed 20610576 ↗
  • Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol. 2005 Mar 17;5(1):5. doi: 10.1186/1471-2377-5-5. PubMed 15774006 ↗
  • Blanchet PJ, Rompre PH. Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia. J Clin Psychopharmacol. 2014 Feb;34(1):36-9. doi: 10.1097/JCP.0b013e3182a6a2e3. PubMed 24145218 ↗
  • Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008 Jul;102(1-3):108-15. doi: 10.1016/j.schres.2008.03.024. Epub 2008 May 20. PubMed 18495435 ↗
  • Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004 Jun 1;68(2-3):283-97. doi: 10.1016/j.schres.2003.09.011. PubMed 15099610 ↗
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005 Nov 15;79(2-3):231-8. doi: 10.1016/j.schres.2005.04.008. Epub 2005 Jun 27. PubMed 15982856 ↗
  • Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y, Francis MM. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018 Sep;199:395-402. doi: 10.1016/j.schres.2018.03.012. Epub 2018 Mar 24. PubMed 29588126 ↗
  • Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, Lambert C, Cardenas-Blanco A, Pine K, Passamonti L, Loane C, Keuken MC, Trujillo P, Lusebrink F, Mattern H, Liu KY, Priovoulos N, Fliessbach K, Dahl MJ, Maass A, Madelung CF, Meder D, Ehrenberg AJ, Speck O, Weiskopf N, Dolan R, Inglis B, Tosun D, Morawski M, Zucca FA, Siebner HR, Mather M, Uludag K, Heinsen H, Poser BA, Howard R, Zecca L, Rowe JB, Grinberg LT, Jacobs HIL, Duzel E, Hammerer D. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019 Sep 1;142(9):2558-2571. doi: 10.1093/brain/awz193. PubMed 31327002 ↗
  • Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006 Jul 1;31(3):968-80. doi: 10.1016/j.neuroimage.2006.01.021. Epub 2006 Mar 10. PubMed 16530430 ↗
  • Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009 Jul 1;46(3):786-802. doi: 10.1016/j.neuroimage.2008.12.037. Epub 2009 Jan 13. PubMed 19195496 ↗
  • Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006 Jul 31;17(11):1215-8. doi: 10.1097/01.wnr.0000227984.84927.a7. PubMed 16837857 ↗
  • Shibata E, Sasaki M, Tohyama K, Kanbara Y, Otsuka K, Ehara S, Sakai A. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn Reson Med Sci. 2006 Dec;5(4):197-200. doi: 10.2463/mrms.5.197. PubMed 17332710 ↗
  • Mullins PG, McGonigle DJ, O'Gorman RL, Puts NA, Vidyasagar R, Evans CJ; Cardiff Symposium on MRS of GABA; Edden RA. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2014 Feb 1;86:43-52. doi: 10.1016/j.neuroimage.2012.12.004. Epub 2012 Dec 13. PubMed 23246994 ↗
  • Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002 Jan 31;33(3):341-55. doi: 10.1016/s0896-6273(02)00569-x. PubMed 11832223 ↗
  • Stikov N, Campbell JS, Stroh T, Lavelee M, Frey S, Novek J, Nuara S, Ho MK, Bedell BJ, Dougherty RF, Leppert IR, Boudreau M, Narayanan S, Duval T, Cohen-Adad J, Picard PA, Gasecka A, Cote D, Pike GB. In vivo histology of the myelin g-ratio with magnetic resonance imaging. Neuroimage. 2015 Sep;118:397-405. doi: 10.1016/j.neuroimage.2015.05.023. Epub 2015 May 21. PubMed 26004502 ↗
  • Berman S, Filo S, Mezer AA. Modeling conduction delays in the corpus callosum using MRI-measured g-ratio. Neuroimage. 2019 Jul 15;195:128-139. doi: 10.1016/j.neuroimage.2019.03.025. Epub 2019 Mar 22. PubMed 30910729 ↗
  • Zhang H, Zhang GF, He ZY, Li ZY, Zhu M, Zhang GX. Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging. J Ovarian Res. 2012 Nov 14;5(1):33. doi: 10.1186/1757-2215-5-33. PubMed 23148860 ↗
  • Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J. 1994 Jan;66(1):259-67. doi: 10.1016/S0006-3495(94)80775-1. PubMed 8130344 ↗
  • Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimination and mapping from diffusion MRI. Magn Reson Med. 2009 Sep;62(3):717-30. doi: 10.1002/mrm.22055. PubMed 19623619 ↗
  • Filo S, Shtangel O, Salamon N, Kol A, Weisinger B, Shifman S, Mezer AA. Disentangling molecular alterations from water-content changes in the aging human brain using quantitative MRI. Nat Commun. 2019 Jul 30;10(1):3403. doi: 10.1038/s41467-019-11319-1. PubMed 31363094 ↗
  • Lee H, Wiggermann V, Rauscher A, Kames C, Beg MF, Popuri K, Tam R, Lam K, Jacova C, Shahinfard E, Sossi V, Pettersen JA, Hsiung GR. Brain Imaging Abnormalities in Mixed Alzheimer's and Subcortical Vascular Dementia. Can J Neurol Sci. 2023 Jul;50(4):515-528. doi: 10.1017/cjn.2022.65. Epub 2022 May 26. PubMed 35614521 ↗
  • Shin HG, Lee J, Yun YH, Yoo SH, Jang J, Oh SH, Nam Y, Jung S, Kim S, Fukunaga M, Kim W, Choi HJ, Lee J. chi-separation: Magnetic susceptibility source separation toward iron and myelin mapping in the brain. Neuroimage. 2021 Oct 15;240:118371. doi: 10.1016/j.neuroimage.2021.118371. Epub 2021 Jul 6. PubMed 34242783 ↗
  • Ben-Eliezer N, Sodickson DK, Block KT. Rapid and accurate T2 mapping from multi-spin-echo data using Bloch-simulation-based reconstruction. Magn Reson Med. 2015 Feb;73(2):809-17. doi: 10.1002/mrm.25156. Epub 2014 Mar 19. PubMed 24648387 ↗
  • Wang Y, Liu T. Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med. 2015 Jan;73(1):82-101. doi: 10.1002/mrm.25358. Epub 2014 Jul 17. PubMed 25044035 ↗
  • Yao B, Li TQ, Gelderen Pv, Shmueli K, de Zwart JA, Duyn JH. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage. 2009 Feb 15;44(4):1259-66. doi: 10.1016/j.neuroimage.2008.10.029. Epub 2008 Nov 5. PubMed 19027861 ↗
  • Weiskopf N, Suckling J, Williams G, Correia MM, Inkster B, Tait R, Ooi C, Bullmore ET, Lutti A. Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. Front Neurosci. 2013 Jun 10;7:95. doi: 10.3389/fnins.2013.00095. eCollection 2013. PubMed 23772204 ↗
  • Lutti A, Dick F, Sereno MI, Weiskopf N. Using high-resolution quantitative mapping of R1 as an index of cortical myelination. Neuroimage. 2014 Jun;93 Pt 2:176-88. doi: 10.1016/j.neuroimage.2013.06.005. Epub 2013 Jun 10. PubMed 23756203 ↗
  • Mezer A, Yeatman JD, Stikov N, Kay KN, Cho NJ, Dougherty RF, Perry ML, Parvizi J, Hua le H, Butts-Pauly K, Wandell BA. Quantifying the local tissue volume and composition in individual brains with magnetic resonance imaging. Nat Med. 2013 Dec;19(12):1667-72. doi: 10.1038/nm.3390. Epub 2013 Nov 3. PubMed 24185694 ↗
  • Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May;154:672-6. doi: 10.1192/bjp.154.5.672. PubMed 2574607 ↗
  • Barnes TR. The Barnes Akathisia Rating Scale--revisited. J Psychopharmacol. 2003 Dec;17(4):365-70. doi: 10.1177/0269881103174013. PubMed 14870947 ↗
  • Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9. doi: 10.1111/j.1600-0447.1970.tb02066.x. No abstract available. PubMed 4917967 ↗
  • Hawley C, Fineberg N, Roberts A, Baldwin D, Sahadevan A, Sharman V. The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide. Int J Psychiatry Clin Pract. 2003;7(4):349-2257. doi: 10.1080/13651500310002986. PubMed 24930422 ↗
  • Dollfus S, Mach C, Morello R. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. Schizophr Bull. 2016 May;42(3):571-8. doi: 10.1093/schbul/sbv161. Epub 2015 Nov 12. PubMed 26564898 ↗
  • Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008 Nov 30;161(2):213-24. doi: 10.1016/j.psychres.2007.11.012. Epub 2008 Oct 11. PubMed 18848731 ↗
  • Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16-23. doi: 10.1034/j.1600-0447.107.s416.5.x. PubMed 12755850 ↗
  • Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993 Dec;(22):39-44. PubMed 8110442 ↗
  • Wongjaikam S, Kumfu S, Khamseekaew J, Chattipakorn SC, Chattipakorn N. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine. Sci Rep. 2017 Mar 13;7:44460. doi: 10.1038/srep44460. PubMed 28287621 ↗
  • Sumneang N, Kumfu S, Khamseekaew J, Siri-Angkul N, Fucharoen S, Chattipakorn SC, Chattipakorn N. Combined iron chelator with N-acetylcysteine exerts the greatest effect on improving cardiac calcium homeostasis in iron-overloaded thalassemic mice. Toxicology. 2019 Nov 1;427:152289. doi: 10.1016/j.tox.2019.152289. Epub 2019 Sep 19. PubMed 31542421 ↗
  • Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean OM, Francis PS, Liu D, Phillipou A, Sarris J, Castle DJ. N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms. Schizophr Bull. 2022 Nov 18;48(6):1263-1272. doi: 10.1093/schbul/sbac065. PubMed 35857752 ↗
  • Dean OM, Mancuso SG, Bush AI, Copolov D, Do KQ, Cuenod M, Conus P, Rossell SL, Castle DJ, Berk M. Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Res. 2015 Dec 30;230(3):982-3. doi: 10.1016/j.psychres.2015.10.037. Epub 2015 Nov 2. No abstract available. PubMed 26626948 ↗
  • Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23. PubMed 18436195 ↗
  • Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, Castle DJ, Tan EJ, Phillipou A, Harris AW, Barreiros AR, Hansen A, Siskind D. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry. 2020 May;54(5):453-466. doi: 10.1177/0004867419893439. Epub 2019 Dec 11. PubMed 31826654 ↗
  • Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garcon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. PubMed 36449420 ↗
  • Filo S, Shaharabani R, Bar Hanin D, Adam M, Ben-David E, Schoffman H, Margalit N, Habib N, Shahar T, Mezer AA. Non-invasive assessment of normal and impaired iron homeostasis in the brain. Nat Commun. 2023 Sep 12;14(1):5467. doi: 10.1038/s41467-023-40999-z. PubMed 37699931 ↗
  • Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Perez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garcon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal. 2018 Sep 10;29(8):742-748. doi: 10.1089/ars.2017.7493. Epub 2018 Feb 8. PubMed 29287521 ↗
  • Catts VS, Weickert CS. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS One. 2012;7(4):e35511. doi: 10.1371/journal.pone.0035511. Epub 2012 Apr 24. PubMed 22545112 ↗
  • Morris G, Berk M, Carvalho AF, Maes M, Walker AJ, Puri BK. Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. Behav Brain Res. 2018 Apr 2;341:154-175. doi: 10.1016/j.bbr.2017.12.036. Epub 2017 Dec 28. PubMed 29289598 ↗
  • Zhang Y, Catts VS, Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust N Z J Psychiatry. 2018 Jul;52(7):690-698. doi: 10.1177/0004867417728805. Epub 2017 Sep 9. PubMed 28891319 ↗
  • Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, Simmonite M, Fiesal J, Katshu MZ, Qureshi A, Skelton M, Christodoulou NG, Brookes MJ, Morris PG, Liddle PF. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry. 2020 Apr;25(4):873-882. doi: 10.1038/s41380-018-0104-7. Epub 2018 Jun 22. PubMed 29934548 ↗
  • Coughlin JM, Yang K, Marsman A, Pradhan S, Wang M, Ward RE, Bonekamp S, Ambinder EB, Higgs CP, Kim PK, Edwards JA, Varvaris M, Wang H, Posporelis S, Ma S, Tsujimura T, Edden RAE, Pomper MG, Sedlak TW, Fournier M, Schretlen DJ, Cascella NG, Barker PB, Sawa A. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Mol Psychiatry. 2021 Jul;26(7):3502-3511. doi: 10.1038/s41380-020-00901-5. Epub 2020 Oct 19. PubMed 33077854 ↗
  • Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6. doi: 10.1073/pnas.0706778104. Epub 2007 Oct 5. PubMed 17921251 ↗
  • Romano A, Serviddio G, Calcagnini S, Villani R, Giudetti AM, Cassano T, Gaetani S. Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radic Biol Med. 2017 Oct;111:281-293. doi: 10.1016/j.freeradbiomed.2016.12.046. Epub 2017 Jan 4. PubMed 28063940 ↗
  • Zhang N, Yu X, Song L, Xiao Z, Xie J, Xu H. Ferritin confers protection against iron-mediated neurotoxicity and ferroptosis through iron chelating mechanisms in MPP+-induced MES23.5 dopaminergic cells. Free Radic Biol Med. 2022 Nov 20;193(Pt 2):751-763. doi: 10.1016/j.freeradbiomed.2022.11.018. Epub 2022 Nov 15. PubMed 36395957 ↗
  • Ravanfar P, Syeda WT, Jayaram M, Rushmore RJ, Moffat B, Lin AP, Lyall AE, Merritt AH, Yaghmaie N, Laskaris L, Luza S, Opazo CM, Liberg B, Chakravarty MM, Devenyi GA, Desmond P, Cropley VL, Makris N, Shenton ME, Bush AI, Velakoulis D, Pantelis C. In Vivo 7-Tesla MRI Investigation of Brain Iron and Its Metabolic Correlates in Chronic Schizophrenia. Schizophrenia (Heidelb). 2022 Oct 26;8(1):86. doi: 10.1038/s41537-022-00293-1. PubMed 36289238 ↗
  • Lotan A, Luza S, Opazo CM, Ayton S, Lane DJR, Mancuso S, Pereira A, Sundram S, Weickert CS, Bousman C, Pantelis C, Everall IP, Bush AI. Perturbed iron biology in the prefrontal cortex of people with schizophrenia. Mol Psychiatry. 2023 May;28(5):2058-2070. doi: 10.1038/s41380-023-01979-3. Epub 2023 Feb 7. PubMed 36750734 ↗
  • Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol. 2006 Sep;291(3):C445-55. doi: 10.1152/ajpcell.00505.2005. Epub 2006 Apr 12. PubMed 16611735 ↗
  • Carlson GC, Lin RE, Chen Y, Brookshire BR, White RS, Lucki I, Siegel SJ, Kim SF. Dexras1 a unique ras-GTPase interacts with NMDA receptor activity and provides a novel dissociation between anxiety, working memory and sensory gating. Neuroscience. 2016 May 13;322:408-15. doi: 10.1016/j.neuroscience.2016.02.063. Epub 2016 Mar 3. PubMed 26946266 ↗
  • White RS, Bhattacharya AK, Chen Y, Byrd M, McMullen MF, Siegel SJ, Carlson GC, Kim SF. Lysosomal iron modulates NMDA receptor-mediated excitation via small GTPase, Dexras1. Mol Brain. 2016 Apr 14;9:38. doi: 10.1186/s13041-016-0220-8. PubMed 27080392 ↗
  • Xu H, Liu X, Xia J, Yu T, Qu Y, Jiang H, Xie J. Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease. FASEB J. 2018 Jun 13:fj201800060RR. doi: 10.1096/fj.201800060RR. Online ahead of print. PubMed 29897813 ↗
  • Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE 3rd, Papadopoulos V, Snyder SH. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron. 2006 Aug 17;51(4):431-40. doi: 10.1016/j.neuron.2006.07.011. PubMed 16908409 ↗
  • Xu H, Jiang H, Xie J. New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases. Front Mol Neurosci. 2017 Mar 16;10:71. doi: 10.3389/fnmol.2017.00071. eCollection 2017. PubMed 28360837 ↗
  • Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa B. Transl Psychiatry. 2021 Oct 14;11(1):528. doi: 10.1038/s41398-021-01607-0. PubMed 34650030 ↗
  • Parellada E, Gasso P. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Transl Psychiatry. 2021 May 6;11(1):271. doi: 10.1038/s41398-021-01385-9. PubMed 33958577 ↗
  • Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021 Jan 23;2021:8881770. doi: 10.1155/2021/8881770. eCollection 2021. PubMed 33552387 ↗
  • Kahn RS, Sommer IE. The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry. 2015 Feb;20(1):84-97. doi: 10.1038/mp.2014.66. Epub 2014 Jul 22. PubMed 25048005 ↗
  • Reddy-Thootkur M, Kraguljac NV, Lahti AC. The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies. Schizophr Res. 2022 Nov;249:74-84. doi: 10.1016/j.schres.2020.02.001. Epub 2020 Feb 24. PubMed 32107102 ↗
  • Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019. PubMed 30890967 ↗
  • Best MW, Grossman M, Oyewumi LK, Bowie CR. Examination of the Positive and Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early psychosis. Early Interv Psychiatry. 2016 Apr;10(2):165-70. doi: 10.1111/eip.12190. Epub 2014 Oct 2. PubMed 25277757 ↗
  • Ventura J, Subotnik KL, Gitlin MJ, Gretchen-Doorly D, Ered A, Villa KF, Hellemann GS, Nuechterlein KH. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015 Feb;161(2-3):407-13. doi: 10.1016/j.schres.2014.10.043. Epub 2014 Dec 8. PubMed 25499044 ↗
  • Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015 Mar 4;1:14005. doi: 10.1038/npjschz.2014.5. eCollection 2015. PubMed 27336027 ↗
  • Austin SF, Mors O, Budtz-Jorgensen E, Secher RG, Hjorthoj CR, Bertelsen M, Jeppesen P, Petersen L, Thorup A, Nordentoft M. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort. Schizophr Res. 2015 Oct;168(1-2):84-91. doi: 10.1016/j.schres.2015.07.021. Epub 2015 Aug 8. PubMed 26265299 ↗
  • Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005 Mar;162(3):495-506. doi: 10.1176/appi.ajp.162.3.495. PubMed 15741466 ↗
  • Hanson E, Healey K, Wolf D, Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep. 2010 Dec;12(6):563-71. doi: 10.1007/s11920-010-0148-0. PubMed 20821286 ↗
  • Vita A, Gaebel W, Mucci A, Sachs G, Erfurth A, Barlati S, Zanca F, Giordano GM, Birkedal Glenthoj L, Nordentoft M, Galderisi S. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022 Sep 5;65(1):e58. doi: 10.1192/j.eurpsy.2022.2316. PubMed 36059109 ↗
  • Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar;37(2):300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17. PubMed 20558531 ↗
  • Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21. PubMed 22356801 ↗
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. PubMed 3616518 ↗
  • Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, Giordano GM, Vandevelde A, Nielsen MO, Glenthoj LB, Sabe M, Pezzella P, Bitter I, Gaebel W. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021 Feb 18;64(1):e23. doi: 10.1192/j.eurpsy.2021.11. PubMed 33597064 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's planned 28 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Aug 12, 2026
StartActual
Aug 12, 2026was Sep 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Hadassah Medical Organization · Jerusalem, Israelno status→Recruiting
  • Jerusalem Mental Health Center · Jerusalem, Israelno status→Not yet recruiting
Sep 29, 2026
Start date
Sep 1, 2026→Aug 12, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Hadassah Medical Organization · Jerusalem, Israelno status→Recruiting
    • Jerusalem Mental Health Center · Jerusalem, Israelno status→Not yet recruiting
    Start date Sep 1, 2026→Aug 12, 2026 (now actual)
    + 1 other change: references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07759895
Lead sponsor
Amit Lotan
Collaborators
Hadassah Medical Organization, Jerusalem Mental Health Center, Hebrew University of Jerusalem
Responsible party
Amit Lotan (Director, Department of Adult Psychiatry and the Biological Psychiatry Lab, Hadassah University Medical Center; Chair, Department of Psychiatry, Hebrew University Medical School, Hadassah Medical Organization) — Sponsor-investigator
First posted
Aug 12, 2026
Start date
Aug 12, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Amit Lotan
Contact
amitlo@hadassah.org.il
+972-2-6777184

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deferiprone

Other studies in this condition

Schizophrenia →

Start the discussion